Factorial Complexity in Cancer Care is Here and Overwhelms!

Genomics-based research is advancing at a pace that it is difficult for any cancer practitioner to interpret, absorb and action. The growing list of biomarker-driven care options compounds the already complex list of factors required for efficient and effective decisions to be made at point of care.

Research in cancer care is at an all-time fever pitch. The Scopus database shows more than 1 million peer-reviewed publications and scientific proceedings on the topic of cancer research since 2008. How can any single physician or practice stay current, sift through and select from this vast library, and ultimately make safe sense of it for her/his patients?

From 1997 to 2003, there were only 27 new cancer drugs approved by the FDA.  From 2004 to 2011, there were another 30. From 2011 to 2017, 92 more were approved.  In 2017, there were more than 630 cancer drugs in late stage clinical trials. Some approvals are “old wine in new bottles” (current drugs approved for new indications), but there are many novel new therapies (immunotherapies and targeted therapies) piling on to the list of therapeutics that practitioners are expected to know, prescribe, manage and adapt to their individual patients’ circumstances. 

Combine this tsunami of peer-reviewed clinical data, scores of new drugs, hundreds of biomarkers to be interpreted, application of next-generation sequencing, and treatment options can only be aptly described as “factorially complex!”   

In one top breast cancer center, the effort to prepare and present just one patient case to a multi-disciplinary tumor board takes over 5 hours of professional staff time.  However, the vast majority of community oncologists (where the majority of US cancer patients are seen) do not have access to tumor boards or the resources to prepare a case for submission to a tumor board. Expecting these oncologists to keep up with “factorially complex” treatment options and provide the right care at the right time in a safe manner to their patients, without the assistance provided by new tools, in order to achieve optimal outcomes in a paradigm that has shifted to patient-specific, comprehensive treatment plans is unrealistic and naïve!

Enter artificial intelligence: personalized treatment relies on gathering, compiling and inferencing data on biomarkers specific to each tumor. An AI platform, like VCurePrecision, curated with 1,000s of rules and updated continuously by a world-leading science team, can bring patient-specific guidance to community oncologists while simplifying the decision-making process and delivering current therapy recommendations, essentially taking the value of a multi-disciplinary tumor board to the fingertips of the community oncologist.

Microprocessors, mobile phones, automobiles, skyscrapers and other complex design problems are all impossible without computer-assisted tools.  Cancer therapy factorial complexity has crossed the point of no return, clinicians are overwhelmed.  Oncologists and cancer patients deserve the power of AI; anything less jeopardizes success and safety. 

--

About VieCure (VieCure and related products are the property of Viviphi Ltd)

We codify the world’s premier cancer guidance from clinical research centers around the world into a technology platform that considers each patient’s unique needs and supports the care team, patient and their family through diagnosis, treatment and follow-up.

VieCure is headquartered in Greenwood Village, Colorado. For more information, visit www.viecure.com.

Contact:
Michael G. Power
Chief Business Development Officer
michael.power@viecure.com

Storm Warning: Old Ways Will Fail in Cancer Care

Storm Warning: Old Ways Will Fail in Cancer Care

Streamlining care with AI decision-support tool. By 2026, there will be ~26 million cancer survivors in America, and more than 2.1 million people who will be newly diagnosed with some form of cancer. Alarmingly, by this timeframe, about 25% of oncologists will be retiring and given current and projected enrollments in medical school, the replacement rate of oncologists will be only 13%.

Intelligent Mobile App Keeps Cancer Patients Out of the ER

Intelligent Mobile App Keeps Cancer Patients Out of the ER

Intelligent mobile app will improve communications between cancer patients and providers and reduce ER visits. Nonadherence to treatment plans is estimated to account for as much as 50 percent of treatment failures overall, and even for cancer patients, whose lives are on the line, adherence can be as low as 14 percent. Technology can help head-off these negative outcomes. Cancer patients become overwhelmed. The complexity and volume of daily medications and symptom monitoring, while they are experiencing life-altering emotional and physical changes, is the perfect setup for mistakes, oversights, stress and hopelessness. Intelligent mobile technology can break these daily tasks into bite-size pieces and deliver them at the right time, relieving a patient’s responsibility to constantly monitor all facets of their care. 

CMS decision transformative for cancer care

CMS decision transformative for cancer care

The Centers for Medicare & Medicaid Services’ (CMS) decision to reimburse for Next Generation Sequencing (NGS) for patients with advanced cancer is a major step to realizing personalized cancer treatment. This reimbursement approval fits perfectly with the expanding use of VieCure’s comprehensive platform for precision cancer care that optimally utilizes NGS within its proprietary VCureEyellation™ AI engine.